Loading stock data...

Welcure Drugs & Pharmaceuticals Limited

BSE: WELCURE

BSE
11.92 -0.62 (-4.94%)

Prev Close

12.54

Open Price

11.92

Volume

1,366,716

Today Low / High

11.92 / 11.92

52 WK Low / High

6.4 / 15.89

Range

11 - 13

The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 11.92, reflecting a change of -0.62 (-4.94418%). The expected target range on the BSE is 11 - 13. The stock is showing a downward trend on the BSE. This could indicate a potential risk for investors who are considering buying at this moment.

22 Aug 11.92 0.00%
21 Aug 12.95 -3.17%
20 Aug 12.70 -2.83%
19 Aug 12.42 -2.58%
18 Aug 12.16 -2.63%
14 Aug 11.90 -2.61%
13 Aug 11.50 -1.39%
12 Aug 11.11 -1.35%
11 Aug 10.59 0.00%
08 Aug 10.09 0.00%
07 Aug 10.86 -2.21%
06 Aug 10.61 -2.45%
05 Aug 10.11 0.00%
04 Aug 9.40 2.45%
01 Aug 9.40 -0.96%
31 Jul 9.90 -2.63%
30 Jul 9.40 0.32%
29 Jul 9.40 1.60%
28 Jul 9.61 -0.31%

Welcure Drugs & Pharmaceuticals Limited Graph

Welcure Drugs & Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Welcure Drugs & Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 11.92, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 11.92 12.04 10.84 - 13.24
12.16 9.73 - 14.59
12.28 8.59 - 15.96
Bearish Scenario 11.92 11.80 10.62 - 12.98
11.68 9.35 - 14.02
11.56 8.09 - 15.03

Overview of Welcure Drugs & Pharmaceuticals Limited

ISIN

INE331C01017

Industry

Medical - Pharmaceuticals

Vol.Avg

1,989,715

Market Cap

1,341,143,040

Last Dividend

0

Official Website

Visit Website

IPO Date

2000-11-27

DCF Diff

17.65

DCF

-6

Financial Ratios Every Investor Needs

Stock Rating Details for WELCURE

Metric Value Recommendation
Overall Rating D+ Strong Sell
DCF Score 1 Strong Sell
ROE Score 1 Strong Sell
ROA Score 1 Strong Sell
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 2 Sell
Price-to-Book (PB) Score 1 Strong Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 24.55 Cr 20.79 Cr 3.76 Cr 0.1533 0.00 Cr 0.00 Cr 0.87 Cr 2.17 Cr 0.19 2.79 Cr 0.0884
2024-03-31 0.00 Cr 0.04 Cr -0.04 Cr 0.0000 0.00 Cr 0.00 Cr -0.18 Cr -0.18 Cr -0.13 -0.14 Cr 0.0000
2023-03-31 0.00 Cr 0.00 Cr 0.00 Cr 0.0000 0.00 Cr 0.03 Cr 0.04 Cr 0.10 Cr 0.08 0.11 Cr 0.0000
2022-03-31 0.11 Cr 0.00 Cr 0.11 Cr 1.0000 0.00 Cr 0.02 Cr 0.02 Cr 0.02 Cr 0.02 0.02 Cr 0.2246
2021-03-31 0.13 Cr 0.00 Cr 0.13 Cr 1.0000 0.00 Cr 0.02 Cr 0.06 Cr 0.06 Cr 0.05 0.00 Cr 0.4136

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 0.13 Cr 266.98 Cr 164.47 Cr 102.5105 Cr 123.20 Cr 123.07 Cr 143.52 Cr 0.03 Cr 0.00 Cr 0.00 Cr 84.73 Cr 41.2688 Cr
2024-03-31 0.02 Cr 1.37 Cr 0.03 Cr 1.3404 Cr 0.00 Cr -0.02 Cr 0.00 Cr 0.02 Cr 0.00 Cr 0.00 Cr 1.29 Cr 0.0306 Cr
2023-03-31 0.00 Cr 1.53 Cr 0.01 Cr 1.5153 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.06 Cr 0.00 Cr 0.00 Cr 0.17 Cr 0.0136 Cr
2022-03-31 0.07 Cr 0.10 Cr 0.00 Cr 0.0930 Cr 0.00 Cr -0.07 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.0038 Cr
2021-03-31 0.05 Cr 0.07 Cr 0.00 Cr 0.0694 Cr 0.00 Cr -0.05 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.0036 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 -222.0082 Cr -0.0635 Cr 222.1989 Cr -222.0252 Cr 0.1067 Cr 0.1283 Cr -0.0635 Cr 2.1701 Cr 123.1989 Cr 0.0000 Cr -143.5236 Cr
2024-03-31 -0.1276 Cr 0.1650 Cr -0.0171 Cr -0.1276 Cr 0.0204 Cr 0.0216 Cr 0.0000 Cr -0.1750 Cr -0.0171 Cr 0.0000 Cr 0.0000 Cr
2023-03-31 0.1069 Cr 1.3205 Cr -1.4922 Cr 0.1069 Cr -0.0648 Cr 0.0012 Cr 0.0000 Cr 0.1017 Cr -1.4922 Cr 0.0000 Cr 0.0000 Cr
2022-03-31 0.0186 Cr 0.0000 Cr 0.0000 Cr 0.0186 Cr 0.0186 Cr 0.0660 Cr 0.0000 Cr 0.0236 Cr 0.0000 Cr 0.0000 Cr 0.0000 Cr
2021-03-31 0.0422 Cr 0.0000 Cr 0.0000 Cr 0.0422 Cr 0.0422 Cr 0.0475 Cr 0.0000 Cr 0.0551 Cr 0.0000 Cr 0.0000 Cr 0.0000 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-06-30 299.91 Cr 268.72 Cr 31.20 Cr 0.1040 31.14 Cr 23.30 Cr 2.07 31.14 Cr 0.0777
2025-03-31 21.21 Cr 17.97 Cr 3.24 Cr 0.1527 0.63 Cr 2.54 Cr 0.23 2.55 Cr 0.1197
2024-12-31 8.84 Cr 7.38 Cr 1.46 Cr 0.1648 0.91 Cr 0.41 Cr 0.04 0.92 Cr 0.0469
2024-09-30 24.55 Cr 20.50 Cr 4.05 Cr 0.1648 1.84 Cr 1.84 Cr 0.23 1.84 Cr 0.0749
2024-06-30 0.00 Cr 0.00 Cr 0.00 Cr 0.0000 -0.35 Cr -0.35 Cr -0.26 -0.34 Cr 0.0000

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-03-31 0.13 Cr 0.00 Cr 0.13 Cr 18.95 Cr 143.52 Cr 182.14 Cr 0.03 Cr 266.98 Cr 164.47 Cr
2024-12-31 0.00 Cr 0.00 Cr 0.23 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -101.83 Cr
2024-09-30 0.23 Cr 0.00 Cr 0.23 Cr 33.17 Cr 143.52 Cr 268.42 Cr 0.03 Cr 269.84 Cr 168.01 Cr
2024-06-30 0.00 Cr 0.00 Cr 0.02 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -1.34 Cr
2024-03-31 0.02 Cr 0.00 Cr 0.02 Cr 0.00 Cr 0.00 Cr 0.03 Cr 0.02 Cr 1.37 Cr 0.03 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2024-12-31 0.41 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 1.84 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 -0.35 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-03-31 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2023-12-31 0.00 Cr 0.01 Cr 0.00 Cr 0.00 Cr 0.01 Cr 0.05 Cr 0.04 Cr 0.00 Cr 0.01 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Medical - Pharmaceuticals

Company Name Symbol Price Market Cap Volume
MedPlus Health Services Limited MEDPLUS ₹821.25 ₹98,339,283,675.00 ₹72,992.00

Key Executives

Company Secretary & Compliance Officer
Ms. Palak Jain

Gender: female

Year Born:

Chief Financial Officer
Mr. Chintan Didawala Ganpat

Gender: male

Year Born:

FAQs about Welcure Drugs & Pharmaceuticals Limited

Who is the CEO of the company?

The CEO is Chintan Didawala Ganpat.

What is the current market price of the stock?

The current price is ₹11.92.

What is the 52-week price range?

The range is ₹6.4-15.89.

What is the market capitalization of the company?

The market capitalization is ₹134.11 crores.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 4.78.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Welcure Drugs & Pharmaceuticals Limited (ISIN: INE331C01017) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹134.11 crores and an average daily volume of 1,989,715 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.

Welcome to the Investing and Trading Information platform: InvesTrack.in

Note: This platform is for educational and informational purposes only. Do not consider anything as financial advice.

QUICK LINKS

Home
About us
Contact us
Privacy Policy
Disclaimer
Sitemap
Investing
Trading
Top Brokers
Tools
Live Analysis

STAY CONNECTED

Follow Us On Social Media
Get Latest Update On Social Media
Facebook Instagram Twitter

General Disclaimer: InvesTrack is an educational platform and not any type of investment advisory platform. Our Blog and videos are based on countless hours of research and experience, which you can use as a guide for your research purposes. None of our content should be considered a piece of investment advice. Earning Disclosure: InvesTrack is a community supported platform. We may earn a commission when you make a purchase through one of our links at no extra cost to you. Note: We are not SEBI Registered Advisors. This website is purely for training and educational purposes. We shall not be responsible for your profit or loss.

© Copyright 2024 - 2025 | InvesTrack